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AIMS: Pandemics impose large demands on the health care system. The supply of appropriate chemotherapeutic
agents, namely oseltamivir solution, presented a serious challenge in the recent influenza pandemic. This study
reports on the rational series of pharmacotechnical steps that were followed to appropriately handle bulk
oseltamivir powder to meet the increased demand.
METHODS: During a six-week period in August and September of 2009, a task force was created in the Central
Pharmacy of Hospital das Clı´nicas to convert imported oseltamivir phosphate into ready-to-use solution for
utilization by physicians and public health authorities. The protocol included dissolution, physico-chemical tests and
the bottling of a liquid microdose formulation for emergency room and outpatient dispensing with adequate
quality control during all phases.
RESULTS: The successful production routine was based on a specially designed flowchart according to which a batch
of 33210 g of oseltamivir powder was converted into 32175 solution units during the aforementioned period with a
net loss of only 2.6%. The end products were bottles containing 50 ml of 15 mg/mL oseltamivir solution. The
measured concentration was stable and accurate (97.5% - 102.0% of the nominal value). The drug was prescribed as
both a prophylactic and therapeutic agent.
DISCUSSION: Hospital pharmacies are conventionally engaged in the manipulation of medical prescriptions and
specialty drugs. They are generally responsible for only small-scale equipment used for manufacturing and quality-
control procedures. The compounding of oseltamivir was a unique effort dictated by exceptional circumstances.
CONCLUSION: The shortage of oseltamivir solution for clinical use was solved by emergency operationalization of a
semi-industrial process in which bulk powder was converted into practical vials for prompt delivery.
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INTRODUCTION
During the last 400 years, there has been an influenza
epidemic approximately every three years and a pandemic
about three times every century. In recent times, the Spanish
Influenza of 1918-1919 is best remembered, which resulted
in a lethality of about 0.5% and up to thirty million deaths
worldwide.1 This unfavorable behavior is explained by
frequent mutation of the viral genome and possible
reassortment with genetic material from related viruses in
animal hosts, which may permit evasion of the host immune
response.
The current swine influenza A is a variant of the H1N1
influenza strain that was responsible for the Spanish Influ-
enza. Fortunately, the current pandemic strain responds to
oseltamivir, a neuraminidase inhibitor that reduces symp-
toms and accelerates recovery.2,3
According to directives of the Brazilian Ministry of Health
and in agreement with the World Health Organization,
institutions in various parts of Brazil were charged with the
local production of oseltamivir during the 2009 pandemic.
Our institution has published a number of reports on the
management of this outbreak.4-6 The Central Pharmacy of
Hospital das Clinicas, Sa˜o Paulo (CPHC), was assigned the
responsibility of preparing the oseltamivir solution.7 The
CPHC met this unusual demand without overlooking
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pharmacotechnical safety and accuracy or the requirements
of good manufacturing practices (GMP).8
These concerns are not exceptional within the pharma-
ceutical industry because they are addressed on a daily
basis by large and specially trained teams. The challenge is
greater within hospital pharmacies, which have less
abundant labor and resources as well as less experience
in handling such unconventional tasks. If one adds the
urgency of a serious epidemic, then the equation becomes
even more complex. Nevertheless, the mission of the CPHC
was to prepare multiple batches of oseltamivir solution for
oral administration to affected patients at short notice.
The aims of this study are to present the processes and
controls adopted by the CPHC that led to the successful
achievement of the set targets.
METHODS
Planning and execution
Within the period of August 6-September 16, 2009, an
emergency task force was defined with the goal of
preparing oseltamivir phosphate vials for clinical use. The
main responsibility was assumed by the pharmacists of the
Pharmacotechnical Unit of the Division of Pharmacy,
Hospital das Clinicas. The sector of non-sterile oral fluids
was mobilized, and selected professionals were assigned to
production, quality control and supervision responsibilities.
The compounding process was based upon the process
described in the product literature provided for oseltamivir
by Roche, Sao Paulo, Brazil, 2 which included basic
information about the salt and its handling. A protocol that
included raw material testing, characterization, dissolution,
bottling and packaging was drafted as a flowchart. Progress
along the flowchart was monitored by the appropriate
physico-chemical tests, and full accountability was provided
by means of careful registration of the final products, yields
and losses, in agreement with GMP.
Production target
The production end point was bottles containing 50 ml
of 15 mg/mL oral Oseltamivir solution (Table 1). This
concentration is the German standard, as described in the
German National Formulary NRF 31.2.3 A minor discre-
pancy with standard manufacturer recommendations can be
noticed (12 mg/mL instead of 15 mg/mL); however, this
dose was considered the most convenient in the pandemic
context. (Table 2).2,3
Quality assurance
International guidelines for quality control were strictly
adopted.9 These guidelines included the analysis of raw
materials, packaging and finished products by the quality
control pharmacist. The identification and inspection of raw
materials was routinely conducted, including initial high
performance liquid chromatography (HPLC) testing.
Storage conditions and handling precautions followed
manufacturer instructions. Safe packaging materials were
employed (amber-colored prescription bottles), and finished
products were examined for cracked or broken units and
incorrect labeling. Batch processing records included the
name of the product, lot number, time of start and com-
pletion of the compounding process, total yield, accidental
losses and the name of the professional in charge. All
deviations from specified procedures were registered and
reviewed.
Finished lots were quarantined until analytical and general
quality control procedures were completed and filed, and
samples were retained. The finished lots were only released
after certification by the responsible pharmacist.
Weekly post-production controls of oseltamivir molecular
content were conducted by HPLC analysis of production lot
samples according to the following schedule: 0 (immediately
after compounding), 7, 14, 21 and 28 days after compounding.
HPLC protocol
The Varian Auto-Sample ProStar 410 HPLC system
(Varian Inc., Palo Alto, CA, USA), equipped with a
ProStar 325 UV-Vis photodiode array detector, ProStar 500
column valve module, and ProStar 230 solvent delivery
module was used for method development and validation.
A Microsorb-MV C8/5-mm (4.6 6 250 mm) column with a
mobile phase of phosphate buffer (pH 6; 0.05 M), methanol
and acetonitrile (620:245:135, v/v) was used at a flow rate of
1.0 mL/min. Sotalol hydrochloride (Bristol-Myers-Squibb,
Sa˜o Paulo, Brazil) was selected as an internal standard, and
an oseltamivir phosphate standard sample (Roche, Sa˜o
Paulo, Brazil) was selected as the external standard. Galaxie
software (Varian, Palo Alto, CA, USA) was employed for
data acquisition. This procedure was adapted from pre-
viously published protocols.3,10
RESULTS
Manufacturing and quality-control processes
The principal pharmacotechnical procedures are described
in Table 3.
Production output
A total batch of 33,230 g of oseltamivir phosphate was
received. This amount of powder was sufficient to produce
9 lots of the solution for a total of 32,175 units of oseltamivir
solution with a net loss of 2.6%.
During 2009, oseltamivir represented about one-quarter
of the total output of the non-sterile oral fluid unit of the
Table 1 - Composition of the Oseltamivir bottles defined
by the Central Pharmacy of Hospital das Clı´nicas.
Ingredient Amount
Oseltamivir phosphate 985 mg *
Sodium benzoate ** 50 mg
Distilled water **** 50 ml ***
(*) Equivalent to 750 mg of oseltamivir; Final concentration 15 mg/mL;
(**) Preservative agent; (***) Actual volume 51 ml in order to comply with
legislation; (****): Volume sufficient for 50 ml;
Table 2 -Manufacturer recommended dosage adopted in
the pandemic context.
Body Weight Daily prescription
0- 1 month 2.0 mg 12/12 h
1- 3 months 2.5 mg 12/12 h
3-12 months 3 mg/kg 12/12 h
15 kg 30 mg 12/12 h
.15 kg to 23 kg 45 mg 12/12 h
.23 kg to 40 kg 60 mg 12/12 h
.40 kg and adults 75 mg 12/12 h
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Division of Pharmacy. The actual percentages according to
released drug bottles or packages were as follows: potas-
sium chloride syrup, 25.8%; oseltamivir phosphate, 25.1%;
codeine drops, 9.4%; aluminum hydroxide, 9.2%; liquid
Vaseline, 7%; sodium bicarbonate, 6.9%; 50% oral glucose
solution, 4.5%; and miscellaneous drugs, 12.1%.
Several techniques adopted in the production flowchart
can be followed in Figures 1-3. The shelf life of the drug was
established as 21 days, although evaluations indicated
excellent stability for longer periods (Figure 4).
Molecular content
The actual concentration of oseltamivir corresponded to
97.5%-102.0% of the nominal value, which is within the accept-
able range for pharmacological and legal purposes.3,11,12
DISCUSSION
The handling of an oral pharmaceutical solution is not
only a matter of solubility, dosage and excipients. Multiple
other variables, such as characterization of the dissolved
drug, stability, dose-uniformity, and palatability or the
absence of chemical irritants, are also important.13
Ingredients must be suitable and compatible, and appro-
priate physical and physico-chemical control methods must
be applied to ensure technical success and to comply with
quality control routines.
GMP regulations have been accepted worldwide and
must be followed. They encompass the design, production,
storage and disposal of the agent, related chemicals,
solvents and other materials. An important feature
of such practices is full accountability of all manipulation
steps.9,11,12
Raw materials, intermediates, and final products should
be weighed and measured or calibrated to ensure accurate
results within appropriate ranges. Complete documentation
at each step of manufacturing is required. Actual yields and
percentages of theoretical yields must be determined at the
conclusion of each phase of processing, packaging, and
storage of the drug solution, and the data must be saved
in specific files. All calculations require independent
confirmation, with the report of a single professional being
insufficient.9,11,12
Oseltamivir phosphate is a precursor of the active
metabolite oseltamivir carboxylate, which is a selective
inhibitor of influenza A and B neuraminidase enzymes.
Neuraminidase participates in viral entry into the cell and in
the subsequent release of virus particles and dissemination
of the infection. Extensive worldwide experience confirms
its value both in the prophylaxis and treatment of endemic
and epidemic influenza outbreaks.2
Oseltamivir is licensed for use in all groups with the
exception of pediatric patients. Dosage flexibility makes it
ideal for epidemics, and although compounding of capsules
was not overlooked by the Brazilian Ministry of Health,
much emphasis was placed on the rapid release of the solu-
tion formulation.7,10
In the report by Albert and Bockshorn, refrigerated
samples of extemporaneously prepared oseltamivir solution
were stable for 84 days, as validated by HPLC. However,
due to the possibility of toxic metabolites, this limit was
lowered to 46 days. In contrast to sterile water, the pH
gradually increased and shelf life diminished to 14 days
with the formation of a precipitate when potable water was
selected.3
Winiarski et al. reported worse results when converting
oseltamivir capsules into oral solutions. Although high-
quality pharmacotechnical procedures were adopted, the
stability under refrigeration was not more than 35 days, and
it decreased to as little as 5 days at room temperature.10
In the current study, excellent stability was demonstrated
for at least 21 days at room temperature, with no detection
Table 3 - Manufacturing flowchart.
Material Features and purposes Routines
Solid ingredients Raw materials Weights, physico-chemical properties, date and time of arrival and
processing, expiry date
Oseltamivir phosphate Active substance Net drug content, solubility, pH, fusion point
Distilled water Dissolving medium pH, total oxidants, electrical conductivity, other physico-chemical
properties, lot and time of preparation
Dissolution and homogenization Oseltamivir phosphate and sodium
benzoate (preservative)
Mixing in steel reactor, filtration, pH, particulate matter and visual
inspection
Final product End point Lot, packaging, labeling and storage, shelf life
Residues and rejected materials Useless and hazardous byproducts Registration of weights, volumes and materials, discarding according to
GMP and environmental legislation
Documentation Quality Control and GMP Initial and final time of each operation, yield, losses , packaging, labeling
and storage, protocol nonconformities and technical problems
Abbreviations: GMP: Good manufacturing practices;
Figure 1 - Fusion point tests of Oseltamivir phosphate.
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of metabolites by HPLC, change in pH or formation of
precipitates.
The results demonstrate that the product was successfully
processed and manufactured, with careful documentation
of each technical step, and that there were negligible errors
or losses. The hurdles of a comparatively small team and
limited resources were circumvented without compromis-
ing the quality or reliability at CPHC, which is not a
standard industrial facility. As mentioned above, its
institutional role is the compounding of commercially
unavailable drugs along with special formulations for
patient use within the 2,000–bed hospital complex.
The 2009 outbreak now looks mild and is partially
forgotten; however, it was a major issue in the initial
months of the pandemic. ‘‘Swine flu’’ was first reported in
Mexico on April 26, 2009. Within less than 50 days, on June
15, it had assumed pandemic proportions with 35,928 cases
and 163 deaths in 76 countries.14 Repeated announcements
by the World Health Organization to all member states
warned about a problem of large proportions.
It was predicted that if the virus achieved equivalent
virulence to that of the 1918-19 pandemic strain, 62 million
people could die. Emergency alerts included travel advi-
sories, stockpiling of antiviral drugs, vaccine development,
and planning for business continuity and maintenance of
essential services.15
Various countries mobilized their disaster management
authorities,15 eventually including the Armed Forces,16 to
Figure 2 - HPLC confirmation of the active ingredient (Oseltamivir phosphate).
Figure 3 - Estimation of the product shelf-life.
Oseltamivir compounding and the (H1N1) influenza pandemic
Marin MLM et al.
CLINICS 2010;65(11):1081-1086
1084
control the outbreak of the swine flu. The European Society
of Intensive Care Medicine established a task force and
issued a special supplement of its journal, defining
recommendations and standard operating procedures for
dealing with the pandemic, which had the potential to
progress to a massive disaster.17,18
Emergency departments in New York hospitals were
overwhelmed in April and May of 2009, and authorities
braced for a public health crisis.19 All of these facts
notwithstanding, the priorities were epidemiological (infor-
mation exchange and biosurveillance efforts), clinical
(screening and therapy) and logistical (manpower, infra-
structure and drug stockpiling).14-19 No report regarding
pharmacotechnical bottlenecks and how to handle them has
been found in the literature.
The principal contribution of this study was not the
creation of innovative manufacturing processes or quality
control criteria, as these were mostly adapted from pub-
lished guidelines and pharmacopeias as well as from
existing CPHC routines.2,3,9-12 Instead, the advance was
achieved by the prompt reaction to the emergency challenge
and the fulfillment of a labor-intensive and exacting mission
within a nontraditional framework of pressing time sche-
dules, heavy workloads and limited resources.
Nevertheless, weaknesses in this production process
should be noted. Production glitches, accidents including
the development of impurities and precipitates, and drug
losses adversely influenced the product yield and shelf
life. As shown, catastrophes were avoided and end points
were quite successfully reached, demonstrating that indis-
pensable pharmacotechnical standards must be adhered to
at all times.
This unique experience could serve as a model for
emergency episodes in the future in case similar difficulties
emerge. It should also stimulate the improvement of the
existing infrastructure and contingency plans so that daunt-
ing or last-minute tasks are minimized. Preparedness is a
requirement for all countries. In recent times, military
strategic thinking has trickled down to civilian life, includ-
ing the health professions.
Every infectious outbreak exhibits different features and
circumstances, and people should be careful not to stockpile
dated ammunition or to fight yesterday’s war. One of the
most important components of the preparedness of any
society is ‘‘institutional memory’’; it is important that
lessons and abilities taught by past events be remembered.
Such intellectual and technical patrimony should not be
simply documented and filed; instead, it should be critically
examined and periodically updated so that it is ready to be
retrieved at any moment.
CONCLUSION
A slow step-wise approach would be the most sensible
choice for the adoption of a new process such as the
preparation and use of oseltamivir solution; however, the
health care system needed the drug immediately. An urgent
solution was thus adopted, with simultaneous planning,
testing and execution of all techniques, following initial
studies for the development of pharmacotechnical methods
and procedures. Although this approach is not recom-
mended as a template for ordinary circumstances, impor-
tant lessons were learned about reactivity and rational crisis
management within the hospital pharmacy.
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